Biontech

Biontech Debt Growth

The Year-over-Year Debt Growth of Biontech (BNTX) as of Oct 16, 2026 is 21.39 %. In the previous year, Year-over-Year Debt Growth was 16.02 % — a change of 33.54% (higher).

Debt Growth

21.39 %

YoY

33.54%

Last updated:

Year-over-Year Debt Growth of Biontech is 2025 21.39 % . Year-over-Year Debt Growth of Biontech was 2024 16.02 % . It decreases by 33.54% higher compared to the previous year.

The Biontech Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2018
600.00 EUR
Jan 1, 2019
414.29 EUR
Jan 1, 2020
229.17 EUR
Jan 1, 2021
27.43 EUR
Jan 1, 2022
-29.80 EUR
Jan 1, 2023
3.35 EUR
Jan 1, 2024
16.02 EUR
Jan 1, 2025
21.39 EUR
The Biontech Debt Growth history
YEARDebt GrowthYoY
21.39 %+33.54%
16.02 %+378.35%
3.35 %-111.24%
-29.80 %-208.66%
27.43 %-88.03%
229.17 %-44.68%
414.29 %-30.95%
600.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biontech Stock analysis

What does Biontech do? BioNTech SE is a German biotech company specializing in the development of innovative therapies for cancer and other serious diseases. The company was founded in 2008 by Ugur Sahin and Özlem Türeci and is headquartered in Mainz. History: BioNTech was established to develop novel treatment options for cancer patients. Originally started as a pure research company, the company has since evolved into a global leader in mRNA-based therapeutics. In recent years, BioNTech has entered into numerous collaborations and partnerships with renowned pharmaceutical companies and other research institutions to strengthen its innovative power and competitiveness. Business model: BioNTech's business model involves developing novel mRNA-based therapeutics for the treatment of cancer and other serious diseases. The company relies on close collaboration with other research institutions and pharmaceutical companies to leverage the latest scientific knowledge and technologies. BioNTech aims to bring its therapeutics to market as quickly as possible to enable more effective treatment for patients worldwide. Divisions: BioNTech is divided into various divisions to optimize its research activities. One of the most important divisions is cancer research, in which the company specifically seeks new treatment options for various types of cancer. BioNTech focuses on the development of personalized cancer immunotherapy tailored to the individual needs of each patient. In this context, the company works closely with other researchers and oncologists to achieve the best possible outcomes. Another important area of BioNTech is vaccine development. The company uses mRNA technology to rapidly and effectively develop vaccines against various infectious diseases. In 2020, BioNTech, together with the US pharmaceutical company Pfizer, brought the first mRNA vaccine against COVID-19 to the market, which has high efficacy and safety. This technology enables rapid response to new pathogens and targeted vaccine development. Products: BioNTech offers a variety of therapeutics and vaccines based on mRNA technology. One of the company's most important products is the mRNA vaccine against COVID-19, which is in use worldwide. In addition, BioNTech develops personalized cancer immunotherapies tailored to the individual characteristics of patients' tumors. Another product of BioNTech is mRNA immunotherapies that can be used for various autoimmune diseases. Conclusion: BioNTech is an innovative biotech company specializing in the development of mRNA-based therapeutics for the treatment of cancer and other serious diseases. With its business model that relies on collaborations and partnerships, the company is able to rapidly and effectively respond to new challenges while staying scientifically up to date. BioNTech has brought a variety of products to the market in a short period of time that have high efficacy and safety, thereby helping patients worldwide. Answer: BioNTech is a German biotech company that specializes in the development of mRNA-based therapeutics for the treatment of cancer and other serious diseases. Biontech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biontech stock

Year-over-Year Debt Growth of Biontech is 21.39 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth Biontech since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's Biontech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Biontech

All Key Metrics — Biontech